OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cristofanilli on the Need for Biosimilars in Oncology

December 16th 2019

Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.

Dr. Fidler on the Utility of Dacomitinib in EGFR-Mutant NSCLC

December 16th 2019

Mary J. Fidler, MD, discusses the utility of dacomitinib (Vizimpro) in patients with EGFR-mutant non–small cell lung cancer.

Dr. Hays on Combining PARP Inhibitors With Immunotherapy in Ovarian Cancer

December 16th 2019

John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.

Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

December 14th 2019

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Dr. Danilov on Utility of Rituximab Biosimilars in CLL

December 14th 2019

Alexey V. Danilov, MD, PhD, discusses the utility of rituximab biosimilars in chronic lymphocytic leukemia.

Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

December 14th 2019

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

December 13th 2019

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

Dr. Pagel on Biosimilars and Cost Consciousness in Oncology

December 13th 2019

John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Saxena on Treatment Options in ALK+ NSCLC

December 13th 2019

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.

Dr. Unger on Utilizing a Multidisciplinary Team in Gastroesophageal Cancer

December 13th 2019

Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.

Dr. Msaouel on Rationale for Sitravatinib/Nivolumab Combo in Urothelial Cancer

December 13th 2019

Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.

Dr. Marron on Shortening Treatment Duration of Immunotherapy in Melanoma

December 12th 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

Dr. Fowler on Types of Surgical Procedures in Ovarian Cancer

December 12th 2019

Jeffrey M. Fowler, MD, discusses the various types of surgical procedures in ovarian cancer.

Dr. Drilon on Treatment Selection Considerations in ALK+ NSCLC

December 12th 2019

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

December 11th 2019

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian Cancer

December 11th 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

December 10th 2019

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Corcoran on the Utility of Regorafenib in CRC

December 10th 2019

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Dr. Parikh on KRAS Inhibitors in Lung Cancer

December 10th 2019

Kaushal Parikh, MD, MBBS, discusses the KRAS inhibitors AMG 510 and MRTX849 in lung cancer.